Blood test may catch melanoma recurrence months before scans

NCT ID NCT06246227

Ongoing Diagnosis Sponsor: Herlev and Gentofte Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test that detects tumor DNA can find melanoma recurrence earlier than standard methods. Researchers will follow 467 high-risk patients who have had primary melanoma removed. If the test works, it could lead to faster treatment and better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: circulating tumor DNA (ctDNA) blood test
What this could lead to: If successful, this blood test could help catch melanoma recurrence earlier than current scans or exams, potentially improving treatment timing and outcomes.
What could go wrong: This is an observational study, not a treatment trial. The test may not detect all recurrences, and earlier detection does not guarantee better survival. Results need validation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Detp. of Pastic and Reconstructive Surgery, Herlev Hospital

Herlev, 2730, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.